CytomX Therapeutics raises $250M through public offering.

CytomX Therapeutics raises $250M through public offering. The biotech company priced 45.99 million shares at $5.30 per share, with an additional 1.18 million pre-funded warrants included in the offering. This capital raise comes as CytomX continues advancing its pipeline of immuno-oncology therapeutics. The $250 million in gross proceeds will likely support research and development efforts, clinical trials, and general corporate operations. Public offerings at this scale reflect investor confidence in the company's scientific approach and market potential. The pricing represents a strategic decision to balance shareholder dilution with the capital needed to accelerate growth and bring treatments to market.